Acute Spinal Cord Injury Clinical Trial
Official title:
A Phase II Study of Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Completely Acute Spinal Cord Injury.
This study is designed to assess the safety and effect of autologous adipose derived stem
cell (ADSCs) transplantation in acute spinal cord injury patients.
1. To assess the safety of autologous ADSCs transplantation in acute spinal cord injury
and the complication after ADSCs transplantation.
2. To evaluate the effect of ADSCs isolation and expansion procedure.
3. To determine if functional outcome is improved following ADSCs transplantation in acute
spinal cord injury patient, using pre-transplantation spinal cord function as the
control.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | March 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 19 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Must be able to give voluntary (patients may not be able to write) consent. - Must be able to understand study information provided to him. - Patients with complete spinal cord < 2 weeks in acute category - The level of spinal cord injury must be categorized at A level in terms of ASIA Impairment scale. - Age should be between 19-60 years - Both male and female Exclusion Criteria: - Support respiration by machine - Melanoma within 5 years - Infectious diseases including HIV and Hepatitis B, C - Brain damage or multiple trauma - Body temperature higher 38 ? or acute disorder - Anemia or thrombocytopenia - Angina , myocardial infarction , heart disease , embolic disease , chronic renal failure, glomerular disease and chronic obstructive pulmonary disease. - Congenital or acquired immunodeficiency disorder - Muscular dystrophy or muscle stiffness - Non-conscious or voice disorders - Treatment with cytotoxic drugs ( immunosuppressive drugs , corticosteroids and cytotoxic drugs) during the clinical trials . - Participating in another clinical trial within 3 months - Other serious disease or disorder can seriously affect the ability to participate in research. - Women who are pregnant or lactating . - Allergy to antibiotics and anesthetics . - Do not agree to participate in research |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Vietnam | Vietnamese- German Hospital | Hanoi |
Lead Sponsor | Collaborator |
---|---|
Tri Phuoc Biotechnology., JSC |
Vietnam,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with adverse events after transplantation. | Number of Participants with adverse events is as a measure of safety and tolerability after ADSC transplantation. Adverse events can be impaired liver and kidney, immunosuppression or immune deficiency, hypersensitivity, anaphylactic shock, meningitis symptoms, etc. | 24 months | Yes |
Secondary | Changes of spinal cord edema in the MRI at the lesion site | Patients take MRI at the lesion site before each injection and after transplantation 6 months, 12 months, 24 months. MRI at the lesion site shows spinal cord edema level is reduced or not. | 24 months | Yes |
Secondary | Urinary and bowel function Improvement | Bladder pressure monitory to assess ability to feel and control urination and bowel. | 24 months | Yes |
Secondary | Muscle contraction force measurement | Comparison the electromyography (EMG) score during contraction of given muscles before each injection and after transplantation 6 months, 12 months and 24 months. | 24 months | Yes |
Secondary | Significant clinical improvement in ASIA impairment scale and general condition. | Patients are assess improvement level based on American Spinal Injury Assessment scale of A,B,C,D or E before and after transplantation. | 24 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04811235 -
Optical Monitoring With Near-Infrared Spectroscopy for Spinal Cord Injury Trial
|
N/A | |
Completed |
NCT00406016 -
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI
|
Phase 1 | |
Recruiting |
NCT05305118 -
TSCS for Acute SCI
|
N/A | |
Recruiting |
NCT05244408 -
"SCRIBBLE" Spinal Cord Injury Blood Biomarker Longitudinal Evaluation
|
||
Recruiting |
NCT05731986 -
Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)
|
N/A | |
Recruiting |
NCT06452264 -
Early Intervention for Information Processing Speed Deficits in Acute SCI: A Pilot Study
|
N/A | |
Recruiting |
NCT05426681 -
Spinal Cord Injury Neuroprotection With Glyburide
|
Phase 1 | |
Recruiting |
NCT04056988 -
tSCI Contrast Enhanced Ultrasound Study
|
Phase 4 | |
Recruiting |
NCT05745298 -
The Use of Functional Electrical Stimulation in Conjunction With Respiratory Muscle Training to Improve Unaided Cough in Individuals With Acute Spinal Cord Injury
|
N/A | |
Terminated |
NCT01750684 -
AC105 in Patients With Acute Traumatic Spinal Cord Injury
|
Phase 2 | |
Recruiting |
NCT04475224 -
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
|
Phase 3 | |
Enrolling by invitation |
NCT06030531 -
Spasticity and Functional Recovery After SCI
|
||
Active, not recruiting |
NCT03935724 -
Stem Cells in Spinal Cord Injury
|
Phase 2/Phase 3 | |
Recruiting |
NCT04054414 -
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
|
Phase 2 | |
Recruiting |
NCT06000592 -
Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI
|
N/A | |
Completed |
NCT02325414 -
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
|
Phase 2 | |
Terminated |
NCT02232165 -
Mean Arterial Blood Pressure Treatment for Acute Spinal Cord Injury
|
N/A | |
Completed |
NCT02260713 -
Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study.
|
Phase 1/Phase 2 | |
Terminated |
NCT02524379 -
Spinal Cord Injury Neuroprotection With Glyburide
|
Phase 1/Phase 2 | |
Completed |
NCT01502631 -
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)
|
Phase 2 |